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http://www.ovarianresearch.com/content/7/1/21RESEARCH Open AccessResveratrol potentiates effects of simvastatin on
inhibition of rat ovarian theca-interstitial cells
steroidogenesis
Israel Ortega1,2, Jesus A Villanueva1, Donna H Wong1, Amanda B Cress1, Anna Sokalska1,3,4, Scott D Stanley5
and Antoni J Duleba1*Abstract
Background: Polycystic ovary syndrome (PCOS) is characterized by ovarian enlargement, hyperplastic theca
compartment and increased androgen production due to, at least in part, excessive expression of several key genes
involved in steroidogenesis. Previously, our group has demonstrated that simvastatin, competitive inhibitor of
3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase), a rate-limiting step of the mevalonate pathway,
reduces rat-theca interstitial cell steroidogenesis by inhibiting Cyp17a1 gene expression, the key enzyme of the
androgen biosynthesis pathway. Recently, we demonstrated that resveratrol, a bioflavonoid abundant in red grapes,
decreases rat theca-interstitial cell steroidogenesis and this suppressive effect is mediated through mechanisms
independent of the mevalonate pathway. The present study evaluated the effect of combining simvastatin and
resveratrol treatments on rat theca-interstitial cell steroidogenesis.
Methods: Rat theca-interstitial cells isolated from 30 day-old female rats were cultured for up to 48 h with or
without simvastatin (1 μM) and/or resveratrol (3-10 μM). Steroidogenic enzymes gene expression was evaluated by
quantitative real time PCR and steroid levels were measured by liquid chromatography-mass spectrometry. Comparisons
between groups were performed using ANOVA and Tukey test.
Results: Resveratrol potentiated inhibitory effects of simvastatin on androstenedione and androsterone production in
theca-interstitial cells. This suppressive effect correlated with profound inhibition in Cyp17a1 mRNA expression in the
presence of a combination of resveratrol and simvastatin.
Conclusions: The present findings indicate that resveratrol potentiates the simvastatin-induced inhibitory effect on
theca-interstitial cell androgen production, raising the possibility of development of novel treatments of PCOS.
Keywords: Androgens, CYP17A1, Ovarian theca-interstitial cells, Resveratrol, Simvastatin, SteroidogenesisBackground
Theca-interstitial cells play a prominent role in folliculo-
genesis, controlling follicle growth and atresia, providing
mechanical support for ovarian follicles and regulating
ovarian steroidogenesis [1]. Differentiation of theca-
interstitial cells from steroidogenically inactive cells into
androgen-producing cells occurs during preantral stages
of follicular development and involves expression of steroid
pathway biosynthetic genes. Under pathological conditions* Correspondence: aduleba@ucsd.edu
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unless otherwise stated.such as polycystic ovary syndrome (PCOS), ovaries are sig-
nificantly enlarged and individual theca cells produce ex-
cessive amounts of androgens due, at least in part, to
increased expression of several genes involved in steroido-
genesis, including STAR, CYP11A1, HSD3B2 and CYP17A1
[2-4]. Among the above-listed genes, overexpression of
CYP17A1, the key gene regulating androgen biosynthesis
pathway, has been shown to play a prominent role in an-
drogen excess in women with PCOS [5,6].
Simvastatin belongs to the family of statins, competi-
tive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase (HMGCR), the rate-limiting
step of the mevalonate pathway. Thus, the effects ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ortega et al. Journal of Ovarian Research 2014, 7:21 Page 2 of 8
http://www.ovarianresearch.com/content/7/1/21statins may be related to decreased availability of several
downstream products of this pathway, such as sub-
strates of isoprenylation: farnesyl pyrophosphate (FPP)
and geranylgeranyl pyrophosphate (GGPP), as well as
reduction of the availability of cholesterol. In addition
to the beneficial effects of statins on cardiovascular dis-
eases due to its cholesterol-lowering action [7,8], these
agents have emerged over the past decade as promising
novel treatments of endocrine disorders such as PCOS
due to their anti-proliferative, androgen-lowering and
anti-inflammatory properties. We have demonstrated
that simvastatin reduces rat theca cell proliferation by
mechanisms involving inhibition of isoprenylation [9,10].
Furthermore, our recent in vitro study has shown that
simvastatin inhibits rat theca-interstitial steroidogenesis
primarily by inhibiting Cyp17a1 mRNA expression, and
this suppressive effect is mediated, at least in part, by de-
creased isoprenylation [10]. In clinical trials, we have
shown that simvastatin treatment improves lipid profile,
decreases systemic inflammation and reduces androgen
levels in women with PCOS [11-13]. However, statins have
potential adverse effects including a recently demon-
strated risk of development of type 2 diabetes [14]. Hence,
there is an urgent need to identify new agents that would
either replace statins or potentiate their beneficial effects
while reducing their adverse effects. We propose that res-
veratrol is such an agent. Notably, clinical use of resvera-
trol has been recently shown to reduce insulin resistance
and likely decrease the risk of development of type 2
diabetes [15].
Resveratrol (trans-3,5,4′-trihydroxystilbene) is a nat-
ural polyphenol produced by several plants to protect
them from pathogens such as bacteria and fungi. This
phytoestrogen is found in grapes, nuts, berries and red
wine and possesses a broad range of beneficial properties
in different tissues, including anti-carcinogenic, cardio-
protective, anti-inflammatory and anti-oxidant [16-19].
Previously, we found that resveratrol promotes apoptosis
and inhibits proliferation in rat theca-interstitial cells,
counteracting the anti-apoptotic and proliferative ef-
fects of insulin [20]. Additionally, we recently demon-
strated that resveratrol reduces androgen production
and Cyp17a1 mRNA gene expression, at least partly,
via inhibition of Akt/PKB phosphorylation in rat theca-
interstitial cells [21].
To date, only a few studies evaluated the potential
beneficial effects of combined therapy using statin in
conjunction with resveratrol. Penumathsa et al. demon-
strated that simvastatin in combination with resveratrol
is more cardioprotective than simvastatin alone using an
ischemic rat heart model [22]. In our recent in vitro
studies, resveratrol potentiated simvastatin-induced in-
hibition of rat theca-interstitial cell proliferation [23], as
well as it augmented the inhibitory effects of simvastatinon cholesterol biosynthesis and HMGCR enzyme activity
in primary cultures of human endometrial stromal
cells [24].
In view of these considerations, we proposed that resvera-
trol may enhance simvastin-induced inhibition in steroido-
genesis, exerting complementary actions on mechanisms
regulating both gene expression and androgen production.
In the present study we evaluated the effect of combin-
ing resveratrol and simvastatin treatments on rat theca-
interstitial cell steroidogenesis. We demonstrated that
resveratrol potentiated inhibitory effects of simvastatin
on androstenedione and androsterone production by
theca-interstitial cells. This suppressive effect correlated
with profound inhibition in Cyp17a1 mRNA expression
in the presence of a combination of resveratrol and
simvastatin.
Methods
Animals
Female Sprague-Dawley rats were obtained at age 22 days
from Charles River Laboratories (Wilmington, MA) and
housed in an air-conditioned environment and a 12-h
light/12-h dark cycle. All animals received standard rat
chow and water ad libitum. At the age of 27, 28 and
29 days, the rats were injected with 17β-estradiol (1 mg/
0.3 ml of sesame oil s.c.) to stimulate ovarian develop-
ment and growth of antral follicles. Twenty-four hours
after the last injection, the animals were anesthetized
using ketamine and xylazine (i.p.) and euthanized by in-
tracardiac perfusion using 0.9% saline. All treatments
and procedures were carried out in accordance with ac-
cepted standards of human animal care as outlined in
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and a protocol approved by
the Institutional Animal Care and Use Committee at the
University of California, Davis.
Cell culture and reagents
The collection and purification of ovarian theca-
interstitial cells were performed as described previously
[25,26]. Briefly, the ovaries were removed from the ani-
mals and dissected free of oviducts and fat under a dis-
secting microscope. After a 60-minute collagenase
digestion, theca-interstitial cells were purified using dis-
continuous Percoll gradient centrifugation. The cells
were counted, and viability, as assessed by the trypan
blue exclusion test, was routinely in the 90%-95% range.
Theca-interstitial cells were incubated for 48 hours in
24-well fibronectin-coated plates at a density of 400,000
cells/well. The cultures were carried out at 37°C in an
atmosphere of 5% CO2 in humidified air in serum-free
McCoy’s 5A culture medium supplemented with 1%
antibiotic/antimycotic mix, 0.1% bovine serum albumin
and 2 mM L-glutamine. The cells were incubated in the
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(1 μM) and/or resveratrol (3-10 μM). The concentrations
of these compounds were selected based on our previous
studies evaluating effects of simvastatin and resveratrol on
ovarian theca-interstitial cell steroidogenesis [10,21]. All
cultures were carried out in the presence of LH (5 ng/ml).
All above chemicals were purchased from Sigma Chemical
Co. (St. Louis, MO) except for LH, which was obtained
from the National Hormone & Pituitary Program at the
Harbor-UCLA Medical Center (Torrance, CA). Each ex-
periment was repeated three times with four replicates in
each experiment.Total RNA isolation and quantitative real-time PCR
Total RNA was isolated using the MagMAX-96 Total
RNA Isolation Kit (Applied Biosystems, Foster City, CA)
and the KingFisher robot (Thermo Scientific, Vantaa,
Finland). Reverse transcription of total RNA to cDNA
was performed using High Capacity cDNA Reverse
Transcription Kit for RT-PCR (Applied Biosystems, CA).
Quantitative real-time PCR reactions were performed
in triplicate using the ABI 7300 Real-time PCR System
(Applied Biosystems, Foster City, CA) and 2X SYBR
Green PCR Master Mix (Applied Biosystem, Warring-
ton, UK). Data were analyzed using SDS 1.4 software
(Applied Biosystems). The relative amount of target
mRNA was expressed as a ratio normalized to hypoxan-
thine phosphoribosyltransferase (Hprt). The primer se-
quences were as described in Table 1.Sample preparation and processing for quantification of
steroids
Each sample was directly assayed; the following extrac-
tion procedure was applied to each specimen. Each sam-
ple aliquot (300 μl) was placed in a 2.0 ml autosampler
vial and spiked with 150 μl of internal standard solution,
i.e., androsteneione-d7 and testosterone-d3. DetectionTable 1 Primers for rat Hprt, Star, Cyp11a, Hsd3b1 and
Cyp17a1
Gene Primer sequence
Hprt Forward: 5'-TTG TTG GAT ATG CCC TTG ACT-3'
Reverse: 5'-CCG CTG TCT TTT AGG CTT TG-3'
Star Forward: 5'- GCC TGA GCA AAG CGG TGT C-3
Reverse: 5'- CTG GCG AAC TCT ATC TGG GTC TGT-3'
Cyp11a1 Forward: 5'- GCT GGA AGG TGT AGC TCA GG-3'
Reverse: 5'- CAC TGG TGT GGA ACA TCT GG-3'
Hsd3b1 Forward: 5'- CCA GAA ACC AAG GAG GAA T-3'
Reverse: 5'- CCA GAA ACC AAG GAG GAA T-3'
Cyp17a1 Forward: 5'- ACT GAG GGT ATC GTG GAT GC-3'
Reverse: 5'- CCG TCA GGC TGG AGA TAG AC-3'and quantitation of all analytes was accomplished using
selective reaction monitoring (SRM).
Androstenedione, androsterone, progesterone and the
deuterated derivative of androsteneione-d7 were obtained
from Steraloids (Newport, RI), whereas testosterone-d3
was obtained from Cerillient (Round Rock, TX). Aceto-
nitrile and methanol were HPLC grade and obtained from
Burdick and Jackson (Muskesgon, MI). Acetone, isopropa-
nol, and ammonium hydroxide were Optima grade and
obtained from Fisher (St. Louis, MO). Formic acid was
ACS grade and obtained from EMD (Gibbstown, NJ).
Mass spectrometry
Simultaneous detection of androstenedione, androster-
one and progesterone was achieved using a novel Tur-
bulent Flow Chromatography HPLC-MS/MS method
described in our previous study [21]. The response for
androstenedione, androsterone, and progesterone were
linear and gave correlation coefficients (R2) ≥ 0.99.
Statistical analysis
Statistical analysis was performed using JMP 9.0 software
(SAS, Cary, NC). Data are presented as the mean ± SEM.
Means were compared by analysis of variance followed by
post-hoc testing using Tukey’s HSD Test. When appropri-
ate, data were logarithmically transformed. A value of
P < 0.05 was considered statistically significant.
Results
Effect of simvastatin and resveratrol on steroidogenic
enzymes gene expression
To evaluate the effect of simvastatin alone and/or resver-
atrol on mRNA expression of the key genes regulating
steroid biosynthesis pathway, theca-interstitial cells were
cultured for 48 h in the absence or presence of simva-
statin (1 μM) and/or resveratrol (3-10 μM). As presented
in Figure 1A, resveratrol did not affect Star mRNA levels
at any of the tested concentrations. Conversely, simva-
statin induced a 1.6-fold increase in Star transcripts
above the control level (P <0.001), whereas the addition
of resveratrol to simvastatin-treated cultures had no sig-
nificant effect on Star mRNA expression compared to the
level attained with simvastatin alone, except for a modest
decrease by 26% (P <0.001) at the highest concentration.
In the same experiments, resveratrol at 10 μM de-
creased Cyp11a1 and Hsd3b1 mRNA expression, re-
spectively, by 38% and 42% (both at P <0.001), whereas
simvastatin did not have any significant effect on either
Cyp11a1 or Hsd3b1 mRNA levels. In contrast, treatment
of cells with simvastatin in combination with 10 μM res-
veratrol decreased both Cyp11a1 and Hsd3b1 mRNA
expression, respectively, by 55% and 43% (both at P
<0.001) below the level observed with simvastatin alone
(Figure 1B-C). Notably, in the presence of simvastatin,
Figure 1 Effect of simvastatin (1 μM) and resveratrol (3-10 μM) on mRNA expression of Star (A), Cyp11a1 (B), Hsd3b1 (C) and Cyp17a1
(D). Theca-interstitial cells were cultured in chemically defined media supplemented with LH (5 ng/ml) for 48 h in the absence (control) or in the
presence of simvastatin and/or resveratrol. Total RNA was isolated, and mRNA expression was determined using quantitative real-time PCR
reactions and normalized to Hprt mRNA levels. Results are presented as a percentage of control. Each bar represents mean ± SEM from three
independent experiments (each with N = 4). Means with no superscripts in common are significantly different (P <0.05).
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achieved by resveratrol alone, whereas simvastatin had
no additive effect on resveratrol-induced decline of
Hsd3b1 mRNA.
The most profound resveratrol-induced inhibitory ef-
fect on mRNA expression was found in Cyp17a1; resver-
atrol at the highest concentration (10 μM) reduced
Cyp17a1 mRNA levels by 73% (P <0.001). Exposure of
cells to simvastatin treatment decreased Cyp17a1 tran-
scripts by 82% (P <0.001) and this simvastatin-induced
inhibitory effect on Cyp17a1 mRNA expression was fur-
ther enhanced to 95% (P <0.001) in the presence of
10 μM resveratrol (Figure 1D).
Effect of simvastatin and resveratrol on steroid
production
To determine the effect of simvastatin alone and/or res-
veratrol on steroid production, levels of progesterone,
androstenedione and androsterone were evaluated inspent media using liquid chromatography-mass spec-
trometry. To account for both simvastatin and resvera-
trol potential effects on the cell number, the production
of steroids was calculated per unit of protein in each in-
dividual culture well and then expressed as percentage
of control cultures. Steroid levels are presented as per-
centage of control in order to facilitate combining of the
results of three separate experiments whereby in each
experiment levels of steroids in control cultures served
as normalizing references. The levels of steroids in con-
trol cultures were as follows: progesterone level ranged
from 5,328 pg/mg to 18,532 pg/mg (Mean = 10,484 pg/
mg), androstenedione level ranged from 392 pg/mg to
3,112 pg/mg (Mean = 1,200 pg/mg) and androsterone
level ranged from 657 pg/mg to 26,786 pg/mg (Mean =
11,053 pg/mg).
As presented in Figure 2A, resveratrol did not affect
progesterone production except for a slight decrease by
20% (P <0.01) at a concentration of 3 μM, whereas
Figure 2 Effect of simvastatin (1 μM) and resveratrol (3-10 μM) on
steroid production by theca-interstitial cell cultures: progesterone
(A), androstenedione (B) and androsterone (C). The cells were
cultured in chemically defined media supplemented with LH (5 ng/ml)
for 48 h in the absence (control) or in the presence of simvastatin
and/or resveratrol. Steroid levels were determined using liquid
chromatography-mass spectrometry. Results are presented as a
percentage of control. Each bar represents mean ± SEM from three
independent experiments (each with N = 4). Means with no superscripts
in common are significantly different (P <0.05).
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tion by 38% (P <0.001). The addition of resveratrol to
simvastatin-treated cultures had no significant effect
compared to the level observed with simvastatin alone at
any of the concentrations tested.
With regard to androgen production, resveratrol induced
a concentration-dependent inhibitory effect: at the highest
concentration (10 μM) androstenedione levels decreased by
76% (P <0.01). Simvastatin alone inhibited androstenedione
production by 83% (P <0.001) and this effect was enhanced
by the addition of resveratrol whereby a combination of
simvastatin and resveratrol at 10 μM reduced andro-
stenedione to non-detectable levels (Figure 2B).
In a similar fashion, resveratrol induced a concentration-
dependent decrease in androsterone levels by up to 76% at
10 μM resveratrol. Simvastatin decreased androsterone
production by 57% (P <0.001), whereas the addition of
10 μM resveratrol potentiated simvastatin-induced inhib-
ition of androsterone levels by additional 25% (P <0.001)
compared to the level attained with simvastatin alone
(Figure 2C).
Discussion
This study demonstrates that in cultures of theca-
interstitial cells: 1) both resveratrol and simvastatin inhibit
androgen production; 2) the simvastatin-induced decrease
in androgen levels is enhanced by the addition of resvera-
trol; 3) the combination of simvastatin and resveratrol de-
creases mRNA levels of key steroidogenic genes compared
to simvastatin alone with particularly profound inhibition
of Cyp17a1 mRNA expression.
The novel finding of the present study is the potentiat-
ing effect of resveratrol on simvastatin-induced inhibition
of steroidogenesis indicating that these compounds may
exert complementary actions on mechanisms regulating
ovarian steroidogenesis. The mevalonate pathway is an
important cellular metabolic pathway that provides cells
with diverse molecules such as cholesterol and substrates
of isoprenylation: farnesyl pyrophosphate (FPP) and gera-
nylgeranyl pyrophosphate (GGPP), which play crucial
roles in cell functions [23]. Isoprenylation consists of the
attachment of lipophilic FPP (farnesylation) or GGPP (ger-
anylation) to the carboxyl terminus of proteins, regulating
the function of several small guanine triphosphatases,
such as Ras. Once this membrane associated GTPase has
been activated, it recruits the serine/threonine kinase Raf
and facilitate its activation. Then, Raf phosphorylates and
stimulates the downstream kinase MEK, which in turn
exhibits a serine/threonine and tyrosine kinase activity,
resulting in the phosphorylation and activation of the
extracellular signal-regulated kinase 1/2 (Erk1/2). The
Ras-Raf-Erk1/2 signaling pathway regulates a large array
of intracellular events, such as proliferation, differenti-
ation, stress response, apoptosis and steroidogenesis. It
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signaling pathway in steroidogenesis is, as yet, poorly
understood, due to conflicting reports demonstrating
stimulation, inhibition or no effect in different steroido-
genic cells [27,28]. The inhibitory effect of statins on the
mevalonate pathway by inhibiting HMGCR, the rate
limiting step of cholesterol synthesis, leads to decreased
availability of several downstream products of the path-
way, including cholesterol and isoprenoids. We specu-
late that simvastatin inhibits theca-cell steroidogenesis
by inhibiting the isoprenylation of Ras and its subse-
quent activity on the Ras-Raf-Erk1/2 signaling pathway.
Consistent with the above considerations, our previous
in vitro study demonstrated that simvastatin-induced
inhibitory effect on theca-interstitial cell steroidogenesis
is mediated, at least in part, by mechanisms involving
decreased isoprenylation [9,10]. Furthermore, we previ-
ously demonstrated that another statin, mevastatin, in-
hibits theca-interstitial cell proliferation by selective
inhibition of basal and insulin-induced activity of the
Erk1/2 pathway [29].
To date, little is known regarding the role that resveratrol
plays in the modulation of the mevalonate pathway. In vivo
studies have shown that resveratrol reduces hepatic
HMGCR expression as well as activity in hamsters and
mice [30,31]. In our recent in vitro study resveratrol inhib-
ited both HMGCR expression and activity in rat theca-
interstitial cells [23]. These effects may be cell-specific since
resveratrol had no significant effect on cholesterol synthesis
and HMGCR activity in a study of rat hepatocytes [32].
Effects of resveratrol on the mevalonate pathway may
be relevant to some and not to other effects on the function
of theca-interstitial cells. We have shown that resveratrol-
induced inhibition of proliferation of rat theca-interstitial
cells is due, at least partly, to reduced isoprenylation [23].
However, in our recent study on effects of resveratrol on
steroidogenesis, we found that the inhibitory effects were
mediated by mechanisms independent of isoprenylation
[21]. Indeed, in the same study we demonstrated that res-
veratrol decreases phosphorylation of Akt/protein kinase
B (PKB), suggesting that selective inhibition of Akt/PKB
pathway activity may be involved in resveratrol-induced
effects on theca cell steroidogenesis.
Thus, a combination of simvastatin and resveratrol may
be blocking separate crucial cell signaling pathways, such
as Ras-Raf-Erk1/2 and Akt/PKB, and hence may exert in-
hibitory and cumulative effects on inhibition of androgen
production. Previously, these pathways have been shown
to be involved in the regulation of ovarian functions such
as gene expression of key steroidogenic genes [33,34]. Fur-
thermore, cross talk between the Akt/PKB and Erk1/2
pathways had been previously described in several cell
types [35]. We speculate that these mechanisms of action
of statin and resveratrol on key signal transductionpathways involved in steroidogenesis may account for the
potentiating effect of resveratrol on simvastatin-induced
inhibition of theca-interstitial cell steroidogenesis.
One potential concern regarding resveratrol pertains
to its low bioavailability. In the present study, resveratrol
actions were evaluated at doses ranging from 3 to 10 μM.
These doses are comparable to those used in previous
studies, whereby resveratrol inhibited both proliferation
and steroidogenesis at concentrations in the range from 1
to 400 μM [21,36,37]. Studies on animal models and clin-
ical trials indicate that these concentrations are likely to
be clinically relevant, since the bioavailability of resveratrol
in both human and rodent models is in the micromolar
range [37,38]. For example, in rodents, resveratrol treat-
ment led to its detection in multiple organs with the high-
est concentration in the kidney (30 μM) and liver (25 μM)
[39], whereas the concentration of trans-resveratrol in the
plasma ranged from 6 to 78.1 μM [40]. In humans, in a
phase I study of oral resveratrol (single doses of 0.5, 1, 2.5,
or 5 g) conducted in 10 healthy volunteers, peak plasma
levels of resveratrol at the highest dose were 2.4 μM,
whereas peak levels of resveratrol metabolites: monog-
lucuronides and resveratrol-3-sulfate were 3- to 8-fold
higher [41]. Therefore, the concentration of resveratrol re-
quired to inhibit steroidogenesis in the present study agrees
with those used in other in vitro studies, indicating that res-
veratrol at pharmacological concentrations may be effective
in reducing steroidogenesis in rat theca-interstitial cells.
In the present study we have demonstrated that a com-
bination treatment with resveratrol and simvastatin is
more effective in decreasing mRNA expression of the sev-
eral genes regulating the steroid biosynthesis pathway
compared to treatment using simvastatin alone. Notably,
the extent of inhibition in Cyp17a1 mRNA expression in-
duced by combination therapy was more profound com-
pared to the effects on other genes involved in the
steroidogenic function of theca-interstitial cells. Interest-
ingly, previous studies of other biological systems have
shown that resveratrol directly inhibits expression of sev-
eral members of the family of human recombinant cyto-
chromes acting as drug-metabolizing enzymes, such as
CYP1A1, CYP1A2 and CYP1B1 [42-44]. A suppression of
Cyp17a1 mRNA expression, the rate-limiting step in the
androgen biosynthesis pathway, decreases the conversion
of progesterone into androstenedione, leading to accumu-
lation of progesterone and decreased biosynthesis of an-
drogens. However, in the present study the combination
treatment with resveratrol and simvastatin dramatically
decreased androstenedione and androsterone production,
whereas levels of progesterone did not change compared
to cultures with simvastatin alone. We propose that des-
pite profound reduction of Cyp17a1 mRNA expression,
progesterone levels did not increase due to a concomitant
modest decrease in mRNA expression of other genes
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Hsd3b1).
These findings may be of clinical relevance and pro-
vide a rationale for the use of a combination therapy
with resveratrol and statins in treatment of hyperandro-
genic conditions such as PCOS. Notably, the presently
observed effects of resveratrol in combination with statin
are likely to correct the key enzymatic aberrations of ste-
roidogenesis by theca cells in women with PCOS. These
aberrations include increased expression of genes regu-
lating the androgen biosynthesis pathway including
STAR, CYP11A1, HSD3B2 and CYP17A1 [2-4,45] as well
as overexpression of Cyp17a1 and increased activity of
17α-hydroxylase/17, 20-lyase which contribute to in-
creased circulating levels of 17-hydroxyprogesterone in
response to gonadrotropin stimulation [6,46].
Conclusion
In conclusion, our results demonstrate for the first time
that resveratrol potentiates the effects of simvastatin on
inhibition of rat theca-interstitial cell androgen production.
These observations may be relevant to the development of
novel therapies aimed to reduce ovarian hyperandrogenism
in women with PCOS.
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